Classical peer review: an empty gun by Smith, Richard
‘If peer review was a drug it would never be allowed onto 
the market,’ says Drummond Rennie, deputy editor of the 
Journal Of the American Medical Association and 
intellec  tual father of the international congresses of peer 
review that have been held every four years since 1989. 
Peer review would not get onto the market because we 
have no convincing evidence of its beneﬁ  ts but a lot of 
evidence of its ﬂ  aws.
Yet, to my continuing surprise, almost no scientists 
know anything about the evidence on peer review. It is a 
process that is central to science - deciding which grant 
proposals will be funded, which papers will be published, 
who will be promoted, and who will receive a Nobel 
prize. We might thus expect that scientists, people who 
are trained to believe nothing until presented with 
evidence, would want to know all the evidence available 
on this important process. Yet not only do scientists 
know little about the evidence on peer review but most 
continue to believe in peer review, thinking it essential 
for the progress of science. Ironically, a faith based rather 
than an evidence based process lies at the heart of 
science.
What is peer review?
Peer review is not easily deﬁ  ned, and every grant giving 
body and journal will have a process that is unique in 
some way. It is clearly something to do with an external, 
third party reviewing a grant proposal or manuscript. But 
how many external reviewers should there be? And under 
what conditions should they review? Should they be 
anony  mous or identiﬁ  ed to authors and readers? And 
who is a peer? Somebody who also researches on the 
subject of the proposal or manuscript or somebody who 
is simply in the same discipline? Should reviewers be 
trained? Diﬀ  erent answers to these questions and many 
others lead to wide variation in systems of peer review.
One useful way of classifying peer review of completed 
studies is into ‘pre-publication’ and ‘post-publication.’ 
When people speak and write about peer review they 
usually mean pre-publication review, the process that 
takes place before a study is published. But what happens 
after publication can also be called peer review, and that, 
I believe, is the peer review that really matters - the 
process whereby the world decides the importance and 
place of a piece of research. Arthur Balfour, a British 
prime minister, might have been speaking of science 
when he famously said that ‘nothing matters much and 
few things matter at all.’ Many studies are never cited 
once, most disappear within a few years, and very few 
have real, continuing importance.
And the correlation between what is judged important 
in pre-publication peer review and what has lasting value 
seems to be small. Fabio Casati, professor of computer 
science at the University of Trento, the holder of 20 
patents, and the founder of a ‘liquid journal’ that had 
dispensed with prepublication peer review, says: 
‘We’ve….found that peer review doesn’t work, in the 
sense that there seems to be very little correlation 
between the judgement of peer reviewers and the fate of 
a paper after publication. Many papers get very high 
marks from their peer reviewers but have little eﬀ  ect on 
the ﬁ  eld. And on the other hand, many papers get average 
ratings but have a big impact’ [1].
Indeed, the correlation could even be inverse in that 
peer review may well be biased against the truly original. 
I return to this point below.
But what is peer review for? (And from now on I shall 
mean pre-publication peer review when I write just ‘peer 
review’. I will also be writing mostly about peer review of 
manuscripts for publication rather than of grants because 
that is what has been studied the most, it is what I know 
best, and it does have a clear alternative - simply 
publishing the manuscript and letting the world decide.) I 
see four main objectives for peer review: selecting what 
should be published, improving what is published, 
detecting errors, and detecting fraud.
Is peer review eff  ective?
Th   e Cochrane Collaboration, the organization that 
through its systematic reviews produces the most reliable 
evidence in medicine and health care, has reviewed the 
evidence on peer review of manuscripts and of grant 
proposals. Th  is is its conclusion on peer review of 
manuscripts: ‘At present, little empirical evidence is 
available to support the use of editorial peer review as a  © 2010 BioMed Central Ltd
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And here is its conclusion on peer review of grant pro-
posals: ‘Th   ere is little empirical evidence on the eﬀ  ects of 
grant giving peer review. No studies assessing the impact 
of peer review on the quality of funded research are 
presently available’ [3].
Of course the absence of evidence and evidence of 
absence of eﬀ   ect are not the same thing, and many, 
particularly the many with a vested interest in peer 
review, continue to believe that peer review is beneﬁ  cial 
but that it has not been studied in the right way. Many 
can also tell anecdotes of how a study they published was 
much improved by peer review. Many can also, however, 
tell anecdotes of bad experiences of peer review, and 
particularly of huge delays caused by peer review with no 
beneﬁ  t. Everybody could perhaps agree that it is shameful 
that a process so central to science should have no 
evidence to support its eﬀ  ectiveness - even if in reality it 
is eﬀ  ective.
If peer review is to be thought of primarily as a quality 
assurance method, then sadly we have lots of evidence of 
its failures. Th   e pretentiously named medical literature is 
shot through with poor studies. John Ioannidis has 
shown how much of what is published is false [4]. Th  e 
editors of ACP Journal Club search the 100 ‘top’ medical 
journals for original scientiﬁ   c articles that are both 
scientiﬁ  cally sound and important for clinicians and ﬁ  nd 
that it is less than 1% of the studies in most journals [5]. 
Many studies have shown that the standard of statistics in 
medical journals is very poor [6].
Sadly we have many examples of studies published in 
medical journals that are not only scientiﬁ  cally poor but 
also have done great damage. Th   e most famous example 
is the Lancet paper that suggested that the MMR 
(measles, mumps, rubella vaccine) caused autism: the 
result was a drop oﬀ   in the number of children vacci-
nated, epidemics of measles, and more than a decade of 
fruitless argument [7]. Another example is the New 
England Journal of Medicine article that seemed to show 
that a new drug for arthritis, rofecoxib, was safer than the 
traditional non-steroidal anti-inﬂ  ammatory drugs because 
it was less likely to cause gastrointestinal bleed  ing [8]. 
Unfortunately, the ﬂ   awed paper hid the increase in 
myocardial infarctions. Th  e paper was important in the 
new drug being widely used and in causing thousands of 
patients to have heart attacks.
Doug Altman, perhaps the leading expert on statistics 
in medical journals, sums it up thus: ‘What should we 
think about researchers who use the wrong techniques 
(either wilfully or in ignorance), use the right techniques 
wrongly, misinterpret their results, report their results 
selectively, cite the literature selectively, and draw 
unjustiﬁ   ed conclusions? We should be appalled. Yet 
numerous studies of the medical literature have shown 
that all of the above phenomena are common. Th  is is 
surely a scandal’ [9].
While Drummond Rennie writes in what might be the 
greatest sentence ever published in a medical journal: 
‘Th  ere seems to be no study too fragmented, no 
hypothesis too trivial, no literature citation too biased or 
too egotistical, no design too warped, no methodology 
too bungled, no presentation of results too inaccurate, 
too obscure, and too contradictory, no analysis too self-
serving, no argument too circular, no conclusions too 
triﬂ  ing or too unjustiﬁ  ed, and no grammar and syntax 
too oﬀ  ensive for a paper to end up in print.’
The downside of peer review
We have little or no evidence that peer review ‘works,’ but 
we have lots of evidence of its downside.
Firstly, it is very expensive in terms of money and 
academic time. At the British Medical Journal we calcu-
lated that the direct cost of reviewing an article was, on 
average, something like £100 and the cost of an article 
that was published was much higher. Th   ese costs did not 
include the cost of the time of the reviewing academics, 
who were not paid by the journal. Th  e Research Infor-
mation Network has calculated that the global cost of 
peer review is £1.9 billion [10]. Th  e cost in time is also 
enormous, and many scientists argue that time spent 
peer reviewing would be better spent doing science.
Th  e cost in time and money is much increased by 
studies working their way down the food chain of journals. 
A study may be submitted to Nature and rejected, then 
sent to the New England Journal of Medicine and rejected, 
and so on through the Lancet, British Medical Journal, 
and several specialist journals before ending up in a local 
journal. Often the same reviewers will be consulted 
repeatedly. And we know that if authors persist long 
enough, you can get anything published.
Th  is expensive and time consuming process might be 
acceptable if it sorted the information eﬀ  ectively, with 
the most important studies being in the most important 
journals. Not only does this not happen (see below) but 
this ineﬀ   ective sorting of information introduces an 
important bias - because the ‘sexier’ articles end up in the 
‘top’ journals. Th   e many people who read these journals 
because they think that they are reading what is most 
important are actually being presented with a distorted 
view of science.
Secondly, peer review is slow. Th  e process regularly 
takes months and sometimes years. Publication may then 
take many more months. A friend of mine, a fellow of the 
Royal Society, has written a paper that I think very 
impor  tant for global health. As I write, it is still un-
published after two years of being reviewed by several 
‘top’ journals. None of the reviewers have raised a major 
ﬂ  aw with the study.
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have shown how if several authors are asked to review a 
paper, their agreement on whether it should be published 
is little higher than would be expected by chance [11]. A 
study in Brain evaluated reviews sent to two neuroscience 
journals and to two neuroscience meetings [12]. Th  e 
journals each used two reviewers, but one of the meetings 
used 16 reviewers while the other used 14. With one of 
the journals the agreement among the journals was no 
better than chance while with the other it was slightly 
higher. For the meetings the variance in the decision to 
publish was 80 to 90% accounted for by the diﬀ  erence in 
opinions of the reviewers and only 10 to 20% by the 
content of the abstract submitted.
A fourth problem with peer reviews is that it does not 
detect errors. At the British Medical Journal we took a 600 
word study that we were about to publish and inserted 
eight errors [13]. We then sent the paper to about 300 
reviewers. Th   e median number of errors spotted was two, 
and 20% of the reviewers did not spot any. We did further 
studies of deliberately inserting errors, some very major, 
and came up with similar results.
Th  e ﬁ  fth problem with pre-publication peer review is 
bias. Th  ere have been many studies of bias - with 
conﬂ  icting results - but the most famous was published 
in Behavioural and Brain Sciences [14]. Th   e authors took 
12 studies that came from prestigious institutions that 
had already been published in psychology journals. Th  ey 
retyped the papers, made minor changes to the titles, 
abstracts, and introductions but changed the authors’ 
names and institutions. Th  ey invented institutions with 
names like the Tri-Valley Center for Human Potential. 
Th  e papers were then resubmitted to the journals that 
had ﬁ   rst published them. In only three cases did the 
journals realise that they had already published the paper, 
and eight of the remaining nine were rejected - not 
because of lack of originality but because of poor quality. 
Th  e authors concluded that this was evidence of bias 
against authors from less prestigious institutions. Most 
authors from less prestigious institutions, particularly 
those in the developing world, believe that peer review is 
biased against them.
Perhaps one of the most important problems with peer 
review is bias against the truly original. Peer review might 
be described as a process where the ‘establishment’ 
decides what is important. Unsurprisingly, the establish-
ment is poor at recognizing new ideas that overturn the 
old ideas. It is the same in the arts where Beethoven’s late 
string quartets were declared to be nothing but noise and 
Van Gogh managed to sell only one painting in his 
lifetime. David Horrobin, a strong critic of peer review, 
has collected examples of peer review turning down 
hugely important work, including Hans Krebs’s descrip-
tion of the citric acid cycle, which won him the Nobel 
prize, Solomon Berson’s discovery of radioimmunoassay, 
which led to a Nobel prize, and Bruce Glick’s identiﬁ  -
cation of B lymphocytes [15].
Finally, peer review can be all too easily abused. 
Reviewers can steal ideas and present them as their own 
or produce an unjustly harsh review to block or at least 
slow down the publication of the ideas of a competitor. 
Th  ese have all happened. Drummond Rennie tells the 
story of a paper he sent, when deputy editor of the New 
England Journal of Medicine, for review to Vijay Soman 
[16]. Having produced a critical review of the paper, 
Soman copied some of the paragraphs and submitted it 
to another journal, the American Journal of Medicine. 
Th   is journal, by coincidence, sent it for review to the boss 
of the author of the plagiarised paper. She realised that 
she had been plagiarised and objected strongly. She 
threatened to denounce Soman but was advised against 
it. Eventually, however, Soman was discovered to have 
invented data and patients and left the country.
Improving peer review
Peer review is often compared with democracy in being 
the least bad system available, and attempts have been 
made to improve peer review - by blinding reviewers to 
the identity of authors, opening up the process so that 
authors and possibly even readers know the identity of 
the reviewers, and training reviewers. In summary, none 
of these methods have made much diﬀ  erence [17,18].
Alternatives to pre-publication peer review
For journal peer review the alternative is to publish 
everything and then let the world decide what is impor-
tant. Th   is is possible because of the internet, and Charles 
Leadbeater has illustrated how we have moved from a 
world of ‘ﬁ  lter then publish’ to one of ‘publish then ﬁ  lter’ 
and a world of ‘I think’ to one of ‘We think’ [19]. Th  e 
problem with ﬁ  ltering before publishing, peer review, is 
that it is an ineﬀ  ective, slow, expensive, biased, ineﬃ   cient, 
anti-innovatory, and easily abused lottery: the important 
is just as likely to be ﬁ  ltered out as the unimportant. Th  e 
sooner we can let the ‘real’ peer review of post-publica-
tion peer review get to work the better.
Fabio Casati puts it thus: ‘If you and I include this paper 
in our journals [our personal collections], we are giving it 
value….When this is done by hundreds of people like us, 
we’re using the selection power of the entire community 
to value the contribution. Interesting papers will rise 
above the noise.’ Th   is is ‘we think’ rather than what a few 
arbitrarily selected reviewers think.
Th   e problem of ﬁ  nding an alternative to peer review of 
grants is more diﬃ   cult - because clearly there are not the 
resources to fund every grant proposal. But it may be 
more important to try and ﬁ  nd an alternative - such as 
giving highly successful scientists funds to pursue what 
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review may mean that important science does not get 
done.
Barriers to change
I recently debated peer review in front of around 80 
people from the Association of Learned and Scholarly 
Publishers. Unsurprisingly, I was arguing against peer 
review. Nobody agreed with my position before my talk - 
and nobody agreed with me afterwards. Th  ese editors 
and publishers were 100% in favour of peer review. Th  e 
majority of scientists are also strongly in favour of peer 
review, although it is less than 100%.
Why are people so strongly in favour of peer review? 
One argument is that we have to have a mechanism, 
albeit an imperfect one, to sort science - otherwise 
people will be overwhelmed with information, much of it 
poor. My responses are this is the case already and that 
far from sorting studies into the important and un-
important the present system delivers misleading signals 
by giving excessive prominence to the ‘scientiﬁ  cally sexy’ 
[20]. I am in favour of sorting, but I think that this works 
better after publication when hundreds of minds and 
publications rather than just one or two decide what they 
think important.
Another argument in favour of peer review, particularly 
in medicine, is that it stops people being misled. Unfor-
tunately, it does not, as I have illustrated. Furthermore, 
many results are made available ﬁ  rst through conferences 
and the mass media - so that even if peer review was 
eﬀ  ective it could not prevent the dissemination of mis-
leading results and conclusions.
My fear is that the real barrier to change is vested 
interest. Th  at £1.9 billion cost of peer review is a great 
many jobs, and, more importantly, it is seen as an essen-
tial part of the £24 billion industry of publishing, distri-
buting, and accessing journal articles, which itself is 14% 
of the costs of undertaking, communicating, and reading 
the results of research. Th   is is not only a great many jobs 
but also considerable revenue and proﬁ  ts for commercial 
publishers and scientiﬁ  c societies that own journals.
But just think what might be done if we were to liberate 
the nearly £2 billion spent on peer review.
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